Literature DB >> 33740169

Personalized IgG Replacement Therapy for Patients with B cell Inborn Errors of Immunity.

Vincent R Bonagura1.   

Abstract

Entities:  

Year:  2021        PMID: 33740169     DOI: 10.1007/s10875-021-00995-8

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


× No keyword cloud information.
  11 in total

1.  Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection.

Authors:  Vincent R Bonagura; Robert Marchlewski; Amanda Cox; David W Rosenthal
Journal:  J Allergy Clin Immunol       Date:  2008-07       Impact factor: 10.793

Review 2.  Update on the use of immunoglobulin in human disease: A review of evidence.

Authors:  Elena E Perez; Jordan S Orange; Francisco Bonilla; Javier Chinen; Ivan K Chinn; Morna Dorsey; Yehia El-Gamal; Terry O Harville; Elham Hossny; Bruce Mazer; Robert Nelson; Elizabeth Secord; Stanley C Jordan; E Richard Stiehm; Ashley A Vo; Mark Ballow
Journal:  J Allergy Clin Immunol       Date:  2016-12-29       Impact factor: 10.793

3.  Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.

Authors:  Jordan S Orange; William J Grossman; Roberta J Navickis; Mahlon M Wilkes
Journal:  Clin Immunol       Date:  2010-08-01       Impact factor: 3.969

4.  Practice parameter for the diagnosis and management of primary immunodeficiency.

Authors:  Francisco A Bonilla; David A Khan; Zuhair K Ballas; Javier Chinen; Michael M Frank; Joyce T Hsu; Michael Keller; Lisa J Kobrynski; Hirsh D Komarow; Bruce Mazer; Robert P Nelson; Jordan S Orange; John M Routes; William T Shearer; Ricardo U Sorensen; James W Verbsky; David I Bernstein; Joann Blessing-Moore; David Lang; Richard A Nicklas; John Oppenheimer; Jay M Portnoy; Christopher R Randolph; Diane Schuller; Sheldon L Spector; Stephen Tilles; Dana Wallace
Journal:  J Allergy Clin Immunol       Date:  2015-09-12       Impact factor: 10.793

5.  The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial.

Authors:  H W Eijkhout; J W van Der Meer; C G Kallenberg; R S Weening; J T van Dissel; L A Sanders; P F Strengers; H Nienhuis; P T Schellekens
Journal:  Ann Intern Med       Date:  2001-08-07       Impact factor: 25.391

6.  High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia.

Authors:  J G Liese; U Wintergerst; K D Tympner; B H Belohradsky
Journal:  Am J Dis Child       Date:  1992-03

Review 7.  The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline.

Authors:  Nadine Shehata; Valerie Palda; Tom Bowen; Elie Haddad; Thomas B Issekutz; Bruce Mazer; Robert Schellenberg; Richard Warrington; David Easton; David Anderson; Heather Hume
Journal:  Transfus Med Rev       Date:  2010-01

Review 8.  Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review.

Authors:  P Wood; S Stanworth; J Burton; A Jones; D G Peckham; T Green; C Hyde; H Chapel
Journal:  Clin Exp Immunol       Date:  2007-06-12       Impact factor: 4.330

9.  A Systematic Review and Meta-regression Analysis on the Impact of Increasing IgG Trough Level on Infection Rates in Primary Immunodeficiency Patients on Intravenous IgG Therapy.

Authors:  Jian Lynn Lee; Noraida Mohamed Shah; Mohd Makmor-Bakry; Farida Hanim Islahudin; Hamidah Alias; Lokman Mohd Noh; Shamin Mohd Saffian
Journal:  J Clin Immunol       Date:  2020-05-16       Impact factor: 8.317

10.  Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies.

Authors:  Pragya Shrestha; Paras Karmacharya; Zhen Wang; Anthony Donato; Avni Y Joshi
Journal:  World Allergy Organ J       Date:  2019-10-09       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.